Change of estrogen receptor, progesterone receptor, and Ki67 after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Document Type : Original Article

Authors

1 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Minia University

2 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Minia University.

3 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Cairo University.

4 Department of Pathology, Faculty of Medicin , Minia University

Abstract

Purpose: The aim of this study is aimed to demonstrate the changes in the estrogen receptor 
(ER), progesterone receptor (PR), Ki-67, after neoadjuvant chemotherapy in the patients with 
locally advanced breast cancer. Materials and Methods: seventy patients who diagnosed 
with locally advanced breast cancer and treated with neoadjuvant chemotherapy. Ki-67, ER, 
PR, tested by immunohistochemistry (IHC) was evaluated before and after neoadjuvant 
chemotherapy. Results: There was a statistically significant reduction in Ki-67, but no 
statistically significant reduction in ER, PR, after neoadjuvant chemotherapy. Conclusion: 
The significant change in the Ki-67 proliferation index may suggest the reduced proliferative 
activity of malignant cells with neoadjuvant chemotherapy.

Keywords

Main Subjects

Files

Share

How to cite

Statistics